Business Context and Reporting Period
This Form 8-K is a current report filed by Vital Therapies, Inc. (noted as Immunics, Inc. in metadata) on May 23, 2018. The filing details the results of the company's 2018 Annual Meeting of Stockholders held on the same date. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
The primary material event reported is the outcome of the Annual Meeting. Of the 42,368,864 shares outstanding as of the March 29, 2018 record date, 31,734,629 shares (approximately 74.90%) were represented at the meeting.
1. Election of Class I Directors
Three nominees were elected to serve until the 2021 annual meeting. The voting results were as follows:
| Nominee | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Jean-Jacques Bienaimé | 17,817,575 | 967,139 | 12,949,915 |
| Russell J. Cox | 18,758,812 | 25,902 | 12,949,915 |
| Errol R. Halperin | 17,865,755 | 918,959 | 12,949,915 |
2. Ratification of Independent Auditor
Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
| For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|
| 31,373,484 | 358,630 | 2,515 | — |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the procedural reporting of the stockholder vote.
Key Facts for Investor Verification
- Company Name Discrepancy: Verify the current legal name of the registrant, as the metadata lists "IMMUNIC, INC." while the filing header explicitly states "VITAL THERAPIES, INC."
- Director Tenure: Confirm the terms of the newly elected Class I directors (Jean-Jacques Bienaimé, Russell J. Cox, and Errol R. Halperin) extend through the 2021 annual meeting.
- Auditor Confirmation: Verify that PricewaterhouseCoopers LLP is the active auditor for the fiscal year ending December 31, 2018.
- Voting Participation: Note that approximately 74.90% of outstanding shares were represented at the meeting, indicating significant shareholder engagement.